Also: A Medicare crisis and doctors’ concerns with Kennedy’s new coronavirus vaccine policy.

Eli Lilly joins up with Camurus to make long-acting versions of the pharma's obesity and diabetes drugs, joining the industry ...

Regeneron Pharmaceuticals has announced that it will be gaining rights to Hansoh Pharmaceuticals’ investigational dual ...

New licensing agreement with Hansoh Pharma provides Regeneron with HS-20094, a GLP-1/GIP receptor agonist in advanced stages of clinical development in China Phase 2 data suggest potentially similar ...

US biotech Regeneron Pharmaceuticals, Inc. (Nasdaq: REGN) today announced a strategic in-licensing agreement with China’s ...

Regeneron Pharmaceuticals (NasdaqGS:REGN) recently announced a strategic in-licensing agreement with Hansoh Pharmaceuticals, acquiring rights for a dual GLP-1/GIP receptor agonist, HS-20094.

Securing access to a GLP-1/GIP receptor agonist will increase the versatility of our clinical programs for obesity and accelerate our mission to support quality, sustained weight loss and the ...

Tirzepatide is now approved for the treatment of obstructive sleep apnea, highlighting the drug class' potential in sleep ...

(UroToday.com) The 2025 American Society of Clinical Oncology (ASCO) Annual Meeting held in Chicago, IL between May 30 and June 3 was host to the Poster Session: Genitourinary Cancer - Prostate, ...

GLP-1 and GIP/GLP-1 receptor agonist use in prostate cancer patients has increased significantly over the past decade. Usage patterns are influenced by age and socioeconomic vulnerability, with ...

Regeneron Pharmaceuticals Inc. is adding to its obesity pipeline by in-licensing Hansoh Biomedical Co. Ltd.’s phase III dual ...

Meanwhile, a team at Brigham and Women's Hospital in Boston is running a four-week pilot study comparing Eli Lilly's dual GIP/GLP-1 tirzepatide to placebo in around 20 AUD patients, focusing on ...